LONDON: Syncona Ltd has signed an agreement for the sale of its portfolio company Clade Therapeutics to Century Therapeutics for $45 million. Century is a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies. Syncona committed $30 million to Clade in August 2021 alongside a syndicate of specialist investors as part of a $87…